Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewL-Quisqualic acid
说明： AMPA agonist; also group I mGlu agonist
化学名： (L)-(+)-α-Amino-3,5-dioxo-1,2,4-oxadiazolidine-2-propanoic acid
纯度： ≥99% (HPLC)
生物活性 for L-Quisqualic acid
L-Quisqualic acid is a glutamate receptor agonist acting at AMPA receptors and metabotropic glutamate receptors positively linked to phosphoinositide hydrolysis. L-Quisqualic acid sensitizes neurons in hippocampus to depolarization by L-AP6 (the so called 'quis' effect).
技术数据 for L-Quisqualic acid
| 分子量 | 189.13 |
| 公式 | C5H7N3O5 |
| 储存 | Store at RT |
| 纯度 | ≥99% (HPLC) |
| CAS Number | 52809-07-1 |
| PubChem ID | 40539 |
| InChI Key | ASNFTDCKZKHJSW-REOHCLBHSA-N |
| Smiles | O=C1N(C[C@]([H])(N)C(O)=O)OC(N1)=O |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶解性数据 for L-Quisqualic acid
| 溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
|---|---|---|---|
| 溶解性 | |||
| 1eq. NaOH | 18.91 | 100 | |
| water | 1.89 | 10 |
制备储备液 for L-Quisqualic acid
以下数据基于产品分子量 189.13。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| 浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 5.29 mL | 26.44 mL | 52.87 mL |
| 5 mM | 1.06 mL | 5.29 mL | 10.57 mL |
| 10 mM | 0.53 mL | 2.64 mL | 5.29 mL |
| 50 mM | 0.11 mL | 0.53 mL | 1.06 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
产品说明书 for L-Quisqualic acid
参考文献 for L-Quisqualic acid
参考文献是支持产品生物活性的出版物。
Littman et al (1995) Effects of quisqualic acid analogs on metabotropic glutamate receptors coupled to phosphoinositide hydrolysis in rat hippocampus. Neuropharmacology 34 829 PMID: 8532164
Porter et al (1992) (S)-Homoquisqualate: a potent agonist at the glutamate metabotropic receptor. Br.J.Pharmacol. 106 509 PMID: 1324071
Schulte et al (1994) Utilization of the resolved L-isomer of 2-amino-6-phosphohexanoic acid (L-AP6) as a selective agonist for a quisqualate-sensitized site in hippocampal CA1 pyramidal neurons. Brain Res. 649 203 PMID: 7953634
If you know of a relevant reference for L-Quisqualic acid, please let us know.
按标靶查看相关产品
按产品操作查看相关产品
关键词: L-Quisqualic acid, L-Quisqualic acid supplier, AMPA, group, I, mGlur, agonists, potent, Glutamate, Receptors, iGlur, Ionotropic, Group, mGlu1, mGlu5, mGluR1, mGluR5, Metabotropic, (Metabotropic), 0188, Tocris Bioscience
9 篇 L-Quisqualic acid 的引用文献
引用文献是使用了 Tocris 产品的出版物。 L-Quisqualic acid 的部分引用包括：
Shin et al (2018) Participation of xCT in melanoma cell proliferation in vitro and tumorigenesis in vivo. Oncogenesis 7 86 PMID: 30425240
Ferré et al (2002) Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function. Proc Natl Acad Sci U S A 99 11940 PMID: 12189203
Wall et al (2014) Disruption of GRM1-mediated signalling using R.zole results in DNA damage in melanoma cells. Pigment Cell Melanoma Res 27 263 PMID: 24330389
Scholler (2017) HTS-compatible FRET-based conformational sensors clarify membrane receptor activation. Nat Chem Biol 13 372 PMID: 28135236
Hu and Tu (2015) The roads to mitochondrial dysfunction in a rat model of posttraumatic syringomyelia. Biomed Res Int 2015 831490 PMID: 25685811
Porter et al (2005) Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J Pharmacol Exp Ther 315 711 PMID: 16040814
Calò et al (2005) Interactions between ephrin-B and metabotropic glutamate 1 receptors in brain tissue and cultured neurons. J Neurosci 25 2245 PMID: 15745950
Mansari et al (2015) Effects of acute and sustained administration of Vort. on the serotonin system in the hippocampus: electrophysiological studies in the rat brain. Psychopharmacology (Berl) 232 2343 PMID: 25665528
Mansari et al (2015) Restoration of serotonin neuronal firing following long-term administration of bupr. but not parox. in olfactory bulbectomized rats. Int J Neuropsychopharmacol 18 PMID: 25522394
您是否知道使用了 Tocris L-Quisqualic acid 的优秀论文？ 请告知我们.
L-Quisqualic acid 的评论
目前没有该产品的评论。 Be the first to review L-Quisqualic acid and earn rewards!
Have you used L-Quisqualic acid?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Alzheimer's Disease Poster
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.